Skip Nav Destination
Issues
1 August 2016
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1055-9965
EISSN 1538-7755
Issue Sections
Highlights
Research Articles
Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer
Kathleen Sturgeon; Laura Digiovanni; Jerene Good; Domenick Salvatore; Desiré Fenderson; Susan Domchek; Jill Stopfer; Mary Lou Galantino; Cathy Bryan; Wei-Ting Hwang; Kathryn Schmitz
Oral Hygiene and Risk of Nasopharyngeal Carcinoma—A Population-Based Case–Control Study in China
Zhiwei Liu; Ellen T. Chang; Qing Liu; Yonglin Cai; Zhe Zhang; Guomin Chen; Shang-Hang Xie; Su-Mei Cao; Jian-Yong Shao; Wei-Hua Jia; Yuming Zheng; Jian Liao; Yufeng Chen; Ingemar Ernberg; Thomas L. Vaughan; Hans-Olov Adami; Guangwu Huang; Yi Zeng; Yi-Xin Zeng; Weimin Ye
Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer
Kathryn L. Taylor; Richard M. Hoffman; Kimberly M. Davis; George Luta; Amethyst Leimpeter; Tania Lobo; Scott P. Kelly; Jun Shan; David Aaronson; Catherine A. Tomko; Amy J. Starosta; Charlotte J. Hagerman; Stephen K. Van Den Eeden
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers
Janet R. Vos; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Jan C. Oosterwijk; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Cora M. Aalfs; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Matti A. Rookus; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Muriel A. Adank; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Annemarie H. van der Hout; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Christi J. van Asperen; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Encarna B. Gómez Garcia; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Arjen R. Mensenkamp; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Agnes Jager; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Margreet G.E.M. Ausems; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Marian J. Mourits; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands; Geertruida H. de Bock; on behalf of the Hereditary Breast and Ovarian Cancer Research Group Netherlands
Null Results in Brief
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds